vs

Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and WIDEPOINT CORP (WYY). Click either name above to swap in a different company.

AbCellera Biologics Inc. is the larger business by last-quarter revenue ($44.9M vs $42.3M, roughly 1.1× WIDEPOINT CORP). WIDEPOINT CORP runs the higher net margin — -2.0% vs -19.9%, a 17.9% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 12.3%). WIDEPOINT CORP produced more free cash flow last quarter ($-270.0K vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 11.2%).

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

WidePoint Corporation is an American company based in Fairfax, Virginia that provides technology-based products and services to the government sector and commercial markets in the United States. The company holds a patent for a digital parsing tool that allows users to access accounts through a secure repository gateway, established using asymmetric authentication employed as public key infrastructure (PKI). WidePoint provides smart card identity verification, wireless expense management, pen...

ABCL vs WYY — Head-to-Head

Bigger by revenue
ABCL
ABCL
1.1× larger
ABCL
$44.9M
$42.3M
WYY
Growing faster (revenue YoY)
ABCL
ABCL
+776.1% gap
ABCL
788.4%
12.3%
WYY
Higher net margin
WYY
WYY
17.9% more per $
WYY
-2.0%
-19.9%
ABCL
More free cash flow
WYY
WYY
$44.3M more FCF
WYY
$-270.0K
$-44.6M
ABCL
Faster 2-yr revenue CAGR
ABCL
ABCL
Annualised
ABCL
112.3%
11.2%
WYY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ABCL
ABCL
WYY
WYY
Revenue
$44.9M
$42.3M
Net Profit
$-8.9M
$-849.4K
Gross Margin
13.8%
Operating Margin
-63.7%
-1.9%
Net Margin
-19.9%
-2.0%
Revenue YoY
788.4%
12.3%
Net Profit YoY
73.9%
-138.3%
EPS (diluted)
$-0.03
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABCL
ABCL
WYY
WYY
Q4 25
$44.9M
$42.3M
Q3 25
$9.0M
$36.1M
Q2 25
$17.1M
$37.9M
Q1 25
$4.2M
$34.2M
Q4 24
$5.0M
$37.7M
Q3 24
$6.5M
$34.6M
Q2 24
$7.3M
$36.0M
Q1 24
$10.0M
$34.2M
Net Profit
ABCL
ABCL
WYY
WYY
Q4 25
$-8.9M
$-849.4K
Q3 25
$-57.1M
$-559.2K
Q2 25
$-34.7M
$-618.5K
Q1 25
$-45.6M
$-724.1K
Q4 24
$-356.4K
Q3 24
$-51.1M
$-425.2K
Q2 24
$-36.9M
$-499.6K
Q1 24
$-40.6M
$-653.1K
Gross Margin
ABCL
ABCL
WYY
WYY
Q4 25
13.8%
Q3 25
14.6%
Q2 25
13.5%
Q1 25
14.0%
Q4 24
12.6%
Q3 24
13.6%
Q2 24
13.6%
Q1 24
13.6%
Operating Margin
ABCL
ABCL
WYY
WYY
Q4 25
-63.7%
-1.9%
Q3 25
-851.8%
-1.3%
Q2 25
-290.2%
-1.9%
Q1 25
-1479.6%
-2.4%
Q4 24
-0.8%
Q3 24
-1439.4%
-1.3%
Q2 24
-1276.2%
-1.3%
Q1 24
-551.5%
-1.9%
Net Margin
ABCL
ABCL
WYY
WYY
Q4 25
-19.9%
-2.0%
Q3 25
-637.8%
-1.5%
Q2 25
-203.3%
-1.6%
Q1 25
-1077.2%
-2.1%
Q4 24
-0.9%
Q3 24
-785.4%
-1.2%
Q2 24
-504.3%
-1.4%
Q1 24
-408.0%
-1.9%
EPS (diluted)
ABCL
ABCL
WYY
WYY
Q4 25
$-0.03
$-0.08
Q3 25
$-0.19
$-0.06
Q2 25
$-0.12
$-0.06
Q1 25
$-0.15
$-0.08
Q4 24
$-0.05
Q3 24
$-0.17
$-0.04
Q2 24
$-0.13
$-0.05
Q1 24
$-0.14
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABCL
ABCL
WYY
WYY
Cash + ST InvestmentsLiquidity on hand
$128.5M
$9.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$966.9M
$11.5M
Total Assets
$1.4B
$79.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABCL
ABCL
WYY
WYY
Q4 25
$128.5M
$9.8M
Q3 25
$83.2M
$12.1M
Q2 25
$92.4M
$6.8M
Q1 25
$159.3M
$3.7M
Q4 24
$156.3M
$6.8M
Q3 24
$126.6M
Q2 24
$148.3M
Q1 24
$123.6M
Stockholders' Equity
ABCL
ABCL
WYY
WYY
Q4 25
$966.9M
$11.5M
Q3 25
$964.0M
$12.2M
Q2 25
$1.0B
$12.6M
Q1 25
$1.0B
$13.0M
Q4 24
$1.1B
$13.6M
Q3 24
$1.1B
$13.8M
Q2 24
$1.1B
$14.0M
Q1 24
$1.1B
$14.2M
Total Assets
ABCL
ABCL
WYY
WYY
Q4 25
$1.4B
$79.8M
Q3 25
$1.4B
$70.6M
Q2 25
$1.4B
$76.6M
Q1 25
$1.3B
$71.4M
Q4 24
$1.4B
$71.6M
Q3 24
$1.4B
$56.9M
Q2 24
$1.4B
$58.6M
Q1 24
$1.5B
$54.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABCL
ABCL
WYY
WYY
Operating Cash FlowLast quarter
$-34.7M
$-173.5K
Free Cash FlowOCF − Capex
$-44.6M
$-270.0K
FCF MarginFCF / Revenue
-99.4%
-0.6%
Capex IntensityCapex / Revenue
21.9%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-174.1M
$5.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABCL
ABCL
WYY
WYY
Q4 25
$-34.7M
$-173.5K
Q3 25
$-52.6M
$5.9M
Q2 25
$-32.4M
$3.2M
Q1 25
$-11.6M
$-3.2M
Q4 24
$-108.6M
$2.4M
Q3 24
$-28.9M
$1.9M
Q2 24
$-30.0M
$-1.1M
Q1 24
$-41.7M
$-1.6M
Free Cash Flow
ABCL
ABCL
WYY
WYY
Q4 25
$-44.6M
$-270.0K
Q3 25
$-61.5M
$5.9M
Q2 25
$-45.8M
$3.1M
Q1 25
$-22.2M
$-3.3M
Q4 24
$-187.0M
$2.4M
Q3 24
$-47.4M
$1.8M
Q2 24
$-50.1M
$-1.1M
Q1 24
$-65.8M
$-1.6M
FCF Margin
ABCL
ABCL
WYY
WYY
Q4 25
-99.4%
-0.6%
Q3 25
-687.0%
16.4%
Q2 25
-267.9%
8.1%
Q1 25
-524.0%
-9.5%
Q4 24
-3702.8%
6.4%
Q3 24
-728.4%
5.3%
Q2 24
-683.8%
-3.0%
Q1 24
-661.5%
-4.6%
Capex Intensity
ABCL
ABCL
WYY
WYY
Q4 25
21.9%
0.2%
Q3 25
99.7%
0.1%
Q2 25
78.2%
0.2%
Q1 25
251.1%
0.1%
Q4 24
1552.7%
0.1%
Q3 24
284.6%
0.2%
Q2 24
274.6%
0.0%
Q1 24
242.5%
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ABCL
ABCL

Segment breakdown not available.

WYY
WYY

Carrier Services$26.8M63%
Managed Services$15.5M37%

Related Comparisons